2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Melanoma
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
11
Carcinoma, Renal Cell
6
Kidney Neoplasms
4
Leukemia, Myeloid, Chronic-Phase
3
Carcinoma, Hepatocellular
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Polycythemia Vera
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Leukemia
2
Hepatitis B, Chronic
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Uveal Melanoma
1
Thrombocytosis
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurofibroma
1
Neoplasms
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
peginterferon alfa-2b
×
Clear all
NCT03554005
2019-07-15
MK-4031-009
Merck Sharp & Dohme LLC
Phase 1
Completed
29 enrolled
11 charts